Jupiter, FL – According to filings with the U.S. Securities and Exchange Commission, Marizyme is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nicholas Devito played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Marizyme

Marizyme is a biotechnology company with clinically tested and patented use of protease therapeutic platform or Krillase for the treatment of acute ischemic stroke, acute myocardial infarction, deep vein thrombosis and chronic wounds/burns. Krillase is classified as a biological drug, however, it has been classified as a Class III medical device in Europe for treating chronic wounds.

To learn more about Marizyme, visit http://marizyme.com/

Contact:
Nicholas Devito, Chief Executive Officer
732-723-7395

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved